ISTH 2025: Abelacimab Demonstrates Low Periprocedural Bleeding Rates in Phase 2 Trial
Jeffrey I. Weitz, OC, MD, FAHA, FRCPC, FACP, FRSC, FACC, FESC, FCAHS, discusses AZALEA-TIMI 71 trial data showing that the long-acting factor XI inhibitor abelacimab is associated with low periprocedural bleeding risk, supporting potential simplification of anticoagulation protocols for most elective and some urgent procedures.
Read More
Psychedelic Science 2025: Lessons From MDMA Trials Could Strengthen Future Psychedelic Approvals
July 28th 2025Joel Stanley of Ajna Biosciences reflects on the regulatory challenges surrounding MDMA-assisted therapy, outlines lessons for future psychedelic drug trials, and emphasizes the importance of scientific rigor, interdisciplinary infrastructure, and the evolving role of pharmacists in ensuring safe clinical integration.
Read More
OTC Case Studies: Family Planning
Essential tips on prenatal vitamins, ovulation kits, pregnancy tests, and emergency contraception for effective family planning and pregnancy preparation.
Read More
Redefining Care Delivery: How Infusion and Specialty Pharmacies Are Converging
July 24th 2025The decentralization of US health care, accelerated by virtual care adoption, shifting reimbursement models, and a growing demand for complex therapies, is elevating the role of specialty and infusion pharmacies as essential, tech-enabled partners in delivering coordinated, patient-centered care across outpatient and home-based settings.
Read More
Remnant Cholesterol, Independent of LDL-C, Serves as Predictor of MASLD
July 24th 2025High levels of remnant cholesterol were associated with increased risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) independent of low-density lipoprotein cholesterol (LDL-C).
Read More